A combination of four 4,000-litre single-use bioreactors reaching a 16,000-litre scale has resulted in the successful completion of WuXi Biologics’ first manufacturing run at its drug substance facility MFG7 in
This is the largest manufacturing scale for the contract research, development and manufacturing organisation's (CRDMO) to date.
The company shared that the Cost of Goods (COGS) from this run is comparable to that of a 16,000-litre traditional stainless-steel bioreactor.
According to
When compared with a traditional 12,000-litre stainless steel bioreactor, this is 6×2,000-litre in the MFG2 and MFG5 facilities and 3×4,000-litre in the MFG5 and MFG8 facilities.
This inaugural run sets the stage for large-scale commercial manufacturing projects at this facility,
Prioritising sustainability and clean energy
As a good manufacturing practice (GMP)-certified facility, its first GMP certificate was achieved just nine months after operations began, the CRDMO confirmed.
Additionally, in
“We are excited to achieve this milestone for the
Building on earlier manufacturing developments
This news follows the company's announcement in September last year, which detailed that had launched new commercial manufacturing facilities in
As an organisation with facilities that utilise next-generation biomanufacturing technologies,
With the notable manufacturing run at its
The post
© Russell Publishing Limited, 2024. All Rights Reserved., source